News

Ablynx and reMYND settle dispute amicably

02-06-2010
Press release | Ablynx nv [Euronext Brussels: ABLX] and reMYND nv announced today that they have reached a settlement concerning a dispute relating to a collaboration agreement to discover and commercialize new Nanobodies® which Ablynx and reMYND entered into in 2003.

reMYND receives a grant of 0.9 million EUR from IWT

10-12-2009
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). Visit the IWT website

reMYND receives license renewal from Schering-Plough for RadarScreen

18-11-2009
Press release | reMYND nv announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic compounds in e

reMYND receives award for Company with an exceptional relevance to society

21-09-2009
On September 21st 2009, reMYND received in the Flemish Parliament 'the 1st Award for Company with an exceptional relevance to society' out of the hands of the Flemish minister-president Kris Peeters.

reMYND awarded by the Michael J. Fox Foundation

21-07-2009
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation for Parkinson's Research in July 2009.

Pages